Big news on TB Tests for psoriasis patients on biologics! New official recommendations say not necessary for IL-17s and IL-23s.  Literally zero cases.  Ever.  
Think nicotinamide prevents skin cancer?  Think again.  Not saying it doesn't, but turns out data isn't really there and the jury is still out. 
How safe are topical steroids?  Depends.  Depends what else you're taking, especially NSAIDS - turns out it may increase your risk of an upper GI pretty substantially.
If somebody doesn't respond adequately to Dupixent, what happens if you switch them to Rinvoq?  Abbvie kind of answered the question, but not really.
Just how well does Rhapsido work in CSU?  And does it actually cause bleeding? No, no it does not.  But we're understanding more and more about why it causes petechiae.  
Are PDE4 inhibitors like apremilast and roflumilast effective for bullous pemphigoid?  Maybe.  
Do Sotyktu (and the new TYK2 inhibitors coming soon) work for atopic dermatitis?  We got our first data and it looks like they are pretty great. 

The Derms on Drugs are back at it, answering the burning derm questions you didn't even know you had.  Join us this week as we dive into more "outside the box" therapies that you can use next week in the office.
-Is low dose naltrexone a lifeline in difficult dermatoses or a false hope?
-There's been some chatter around metformin for hidradenitis suppurativa.  Is it hype or hope?
-Diet and chronic spontaneous urticaria - Patients always ask and while we know it isn't food allergy, new data says that diet does play a role and gives us a simple intervention that's worth trying.
-Everybody hates warts and we're always looking for pain free treatment options - could a heating pad and hydrogen peroxide be the answer?
-Can we knock out psoriasis long term with a few months of high dose IL-23 inhibition?
-We love tranexamic acid for melasma, but does oral or topical work better?
-Once a vitiligo patient gets better, can you stop the Opzelura?
-Fact or Fiction:  Compared to PLEVA, PLC lasts longer and happens in adults more than kids?

The Derms on Drugs are joined by Dr. Peter Lio to take a dive into the "root causes" of atopic dermatitis and what we can do to address them.  Maybe you've heard about the "NICE" Axis - the Neuro-Immuno-Cutaneo-Endocrine Axis and thought you were on the cutting edge.  Well, you're not.  The new and updated model is the "SINGE" Network - the Skin-Immuno-Neuro-Gastro-Endocrine Network.  Join us this week to get the answers to more of the questions you didn't know you should have!

• New data confirms again that elimination diets don't help with atopic dermatitis and data shows that avoiding foods makes you more likely so how do you talk to patients who are convinced food allergy is driving their atopic dermatitis?
• Should you be recommending probiotics to you atopic dermatitis patients (and which one)?
• How (and why) do probiotics work for atopic dermatitis?
• What does a lion in your basement have to do with atopic dermatitis?
• How do you handle patients who say that all moisturizers sting when you put them on?
• How do you deal with people in whom Staph aureus is playing a major role in their atopic dermatitis?
• What's coming for atopic dermatitis in 2026?

This week's episode will help you not get sued, talk to psoriasis patients about diet, manage transplant patients with skin cancer and more.  Join us again this week to get the answers to burning dermatology questions you didn't know you had.   
Can the Mediterranean diet help with psoriasis?  And why do people get 'gluten sensitivity' from US wheat but not Mediterranean wheat?

When do you recommend changing immunosuppression in transplant patients with skin cancer?

Are people with atopic dermatitis more or less likely to have contact derm than other people?

Hailey Hailey is an awful disease that's hard to treat - can dupilumab help?  What other 'off the beaten path' therapies are there?

Cosibelimab is the new kid on the block for bad squamous cell carcinoma - is it any better than existing treatments?

When do you need to be worried about underlying malignancy in dermatomyositis patients?

Oral minoxidil causes hairy arms in men.  But do they care?

You know Bactrim can cause SJS and TEN, but do you know about the other life threatening side effect that specifically affects young healthy people with acne?

The Derms on Drugs bring in a heavy hitter straight out of silicon valley to talk AI and the future of dermatology.  Dr. Faranak Kamangar is a Board Certified Dermatologist who founded, built and continues to improve DermGPT - a derm specific LLM that just outperformed ChatGPT in a head-to-head contest judged by dermatologists!  As usual, we'll answer the questions you didn't know you had (well, maybe you knew you had some of these):

• Is AI going to make our lives easier or is it going to replace us?
• How good is AI at answering patient questions?
• Will patients accept "AI Providers"?
• How can you start levering AI now to make your life better?
• What AI tools are out there to start using right now?
• Are AI scribes all that great?

The Derms on Drugs give the definitive answer to the age old question:  What came first, the chicken or the egg?  You'll have to listen to find out.  

• What's a Mazotti Reaction and why do you care?

• How do JAK inhibitors compare to dupilumab for treating prurigo nodularis?
• What's a cheap, easy, safe, effective treatment for palmoplantar pustulosis?
• Can a steroid nasal spray help for Chronic Spontaneous Urticaria?
• Do biologics reduce infection risk in AD more than JAK Inhibitors and why?
• How does superficial radiation therapy compare to Mohs for skin cancer?
• Dermal hyperpigmentation is impossible to treat - can isotretinoin help?
• Cheilitis drives derms and patients nuts - what's the new, cheap, easy way to help?

Get ready for a no-nonsense tour-de-force of practical application in the latest derm literature. Pipeline drugs, new approvals, brand names, generics—and HS data you’re better off ignoring (we’ll tell you why).

In this episode:

·       Leqselvi: the newest JAK for alopecia areata—actually different, or more of the same?

·       HS & spondyloarthritis: are you screening… should you be?

·       JAKs and the heart: are all cardiovascular risks created equal?

·       “2/3 HS remission” headlines: why this data shouldn’t change your practice

·       Tirbanibulin + cryo for AKs: combo win or marketing math?

·       Hydrochlorothiazide & skin cancer: do you really need that conversation?

·       Oral minoxidil + Olumiant: synergy or wishful thinking in AA?

·       OX40/OX40L blockers: exciting pathway—new hope or new hype?

Fast. Practical. Slightly skeptical (for good reason).

If you prescribe, counsel, or roll your eyes at bad data—this one’s for you.

Listening this week could save your life (well, at least your kidneys).  Find out what common ingredient in keratin treatments you (and your friends, family and patients) NEED to avoid.  But there's a lot more than that packed into this week's episode.  As always, the Derms on Drugs bring the goods on the latest questions that the literature is answering:
-Is isotretinoin making kids short?  
-Is Dupixent making them tall?  
-What is "transcutaneous auricular vagus nerve stimulation" and which common but difficult derm disease does it help with?  
-What OTC supplement makes NBUVB work better for vitiligo?  
-What oral drug can you add to isotretinoin to make it work even better?  
-Does oral tranexamic acid increase the risk of blood clots when used in dermatology?
-How well does Opzelura work for hidradenitis suppurativa?
-Do Humira biosimilars work as well as Humira in hidradenitis suppurativa?
-What common statistical technique used by pharma is total BS?
-Which ingredient in 'keratin treatments" is causing kidney failure and kidney stones? 

Admit it—bad hair days are the worst. Now imagine every day is one. Alopecia’s psychological impact is way deeper (and more surprising) than most people think. This week, the Derms on Drugs sit down with Harvard’s Dr. Maryanne Makredes Senna to unpack the mental side of AA—and then dive into what to do when a JAK inhibitor just… doesn’t JAK. As always, we’re answering the questions you didn’t even know you had.

Here’s what we’re tackling:

• What hits harder on anxiety and depression—scarring or non-scarring alopecia?

• How tightly does AA severity track with psychological burden?

• How should you approach the mental health effects of AA?
  (Yes, you should ask. No, you shouldn’t be the one treating—here’s how to bridge patients to the right therapists.)

• And what do you do when a JAK Inhibitor isn’t giving you the results you hoped for?

This week, the Derms on Drugs are back with another literature speed-run—think 3D chess meets derm nerd nirvana. We’re answering questions you didn’t even know you had (and a few you wish you didn’t).

Here’s what we’re tackling:

• Do herbal supplements turn up dermatomyositis?

• Can biologics cut down on blood clots in HS?

• Wait… does Claritin supercharge isotretinoin?

• Is Sotyktu stirring up rosacea?

• How good is the new oral IL-23 inhibitor icotrokinra for psoriasis?

• Any fresh weapons against demodex?

• Anything new for those stubborn pemphigus oral lesions?

• What to do when your patient is resistant to multiple botulinum toxins?

• And—holy grail alert—can we actually prevent chemo-induced alopecia in breast cancer?